Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study

被引：10

作者：

Fasching, P. A. ^{[1
]}

Fehm, T. ^{[2
,39
]}

Kellner, S. ^{[3
]}

de Waal, J. ^{[3
]}

Rezal, M. ^{[4
]}

Baler, B. ^{[3
]}

Baake, G. ^{[5
]}

Kolberg, H. -C ^{[6
]}

Guggenberger, M. ^{[7
]}

Warm, N. ^{[3
,8
,9
]}

Harbeck, N. ^{[29
]}

Wuerstlein, R. ^{[10
]}

Deuker, J. -U ^{[11
,21
]}

Dall, P. ^{[12
,31
]}

Richter, B. ^{[32
]}

Wachsmann, G. ^{[13
]}

Brucker, C. ^{[14
]}

Siebers, J. W. ^{[15
]}

Fersis, N. ^{[16
]}

Kuhn, T. ^{[17
]}

Wolf, C. ^{[18
]}

Vollert, H. -W ^{[19
]}

Breitbach, G. -P ^{[20
,22
]}

Janni, W. ^{[21
]}

Landthaler, R. ^{[22
]}

Kohls, A. ^{[23
,33
]}

Rezek, D. ^{[24
,28
]}

Nosslet, T. ^{[25
,27
]}

Fischer, G. ^{[26
]}

Henschen, S. ^{[28
]}

Praetz, T. ^{[29
]}

Heyl, V. ^{[35
]}

Kuehn, T. ^{[30
,32
]}

Krauss, T. ^{[31
]}

Thomssen, C. ^{[32
]}

Kuemmel, S. ^{[33
]}

Hohn, A. ^{[34
]}

Tesch, H. ^{[35
]}

Mundhenke, C. ^{[31
]}

Hein, A. ^{[1
,33
]}

Rauh, C. ^{[1
]}

Bayer, C. M. ^{[1
]}

Jacob, A. ^{[37
]}

Schmidt, K. ^{[37
]}

Belleville, E. ^{[31
]}

Hadji, P. ^{[38
]}

Wallwiener, D. ^{[39
]}

Grischice, E. -M ^{[36
,39
]}

Beckmann, M. W. ^{[1
]}

Brucker, S. Y.

机构：

[1] Univ Erlangen Nurnberg, Univ Brustzentrum Franken, Frauenklin, Comprehens Canc Ctr Erlangen EMN,Univ Klinikum Er, D-91054 Erlangen, Germany

[2] Univ Frauenklin Dusseldorf, Dusseldorf, Germany

[3] Frauenklin Klinikum Dachau, Dachau, Germany

[4] Luisenkrankenhaus Dusseldorf, Dusseldorf, Germany

[5] Klinikum Pinneberg, Pinneberg, Germany

[6] Marienhosp Bottrop, Bottrop, Germany

[7] Klinikum Tuttlingen, Tuttlingen, Germany

[8] Univ Frauenklin Koln, Brustzentrum, Cologne, Germany

[9] Klinken Stadt Koln gGmbH Holweide, Brustzentrum, Cologne, Germany

[10] Univ Munich, Brustzentrum, Frauenkliniken Grosshadern & Maistr Innenstad, Munich, Germany

[11] Klinikum Luneburg, Frauenklin, Luneburg, Germany

[12] Elblandkliniken Meissen Radebeul Standort Radebeu, Radebeul, Germany

[13] Kreiskrankenhaus Boblingen, Boblingen, Germany

[14] Paracelsus Med Privatuniv, Univ Klin Frauenheilkunde, Nurnberg, Germany

[15] St Josefklin Offenburg, Frauenklin, Offenburg, Germany

[16] Klinikum Bayreuth GmbH, Comprehens Canc Ctr Erlangen EMN, Frauenklin, Bayreuth, Germany

[17] Karl Olga Krankenhaus, Stuttgart, Germany

[18] Med Zentrurn Ulm, Ulm, Germany

[19] Klinikum Friedrichshafen, Friedrichshafen, Germany

[20] Stadt Klinikum Neunkirchen Gynakol & Geburtshilfe, Neunkirchen, Germany

[21] Univ Ulm Klinikum, Frauenklin, Ulm, Germany

[22] Gynakol Praxis Kreisklin, Krumbach, Germany

[23] Evangel Krankenhaus Ludwigsfelde Teltow, Ludwigsfelde, Germany

[24] Marien Hosp Wesel, Wesel, Germany

[25] Frauenklin Kreiskrankenhaus Hameln, Hameln, Germany

[26] Landkreis Mittweida Krankenhaus gGmbH, Mittweida, Germany

[27] Johanniter Krankenhaus Genthin Stendal gGmbH, Stendal, Germany

[28] Praxis Dr Praetz, Bad Mergenlheim, Germany

[29] Asklepios Paulinen Klin Wiesbaden, Wiesbaden, Germany

[30] Stadt Kliniken Esslingen aN, Frauenklin, Esslingen, Germany

[31] Frauenklin Lippe, Lippe, Germany

[32] Univ Klin Halle Wittenberg, Frauenklin, Halle, Germany

[33] Evang Huyssens Stiftung Knappschaft GmbH, Kliniken Essen Mitte, Brustzentrum, Essen, Germany

[34] Kreiskrankenhaus Rendsburg, Rendsburg, Germany

[35] Onkol Bethanien, Frankfurt, Germany

[36] Univ Klinikum Schleswig Holstein Campus Kiel, Kiel, Germany

[37] Novartis Pharma GmbH, Nurnberg, Germany

[38] Krankenhaus NW Frankfurt, Klin Gynakol & Gebursthilfe, Frankfurt, Germany

[39] Univ Frauenklin Tubingen, Tubingen, Germany

来源：

GEBURTSHILFE UND FRAUENHEILKUNDE | 2014年 / 74卷 / 12期

关键词：

breast cancer; aromatase inhibitor; compliance; endocrine therapy; ADJUVANT ENDOCRINE THERAPY; PATIENTS ANASTROZOLE COMPLIANCE; RANDOMIZED-TRIAL; TAMOXIFEN THERAPY; PACT PROGRAM; WOMEN; EXEMESTANE; COMBINATION; ADHERENCE;

D O I：

10.1055/s-0034-1383401

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Introduction: The EvaluateTM study (Evaluation of therapy management and patient compliance in postmenopausal hormone receptor-positive breast cancer patients receiving letrozole treatment) is a prospective, non-interventional study for the assessment of therapy management and compliance in the routine care of postmenopausal women with invasive hormone receptor-positive breast cancer receiving letrozole. The parameters for inclusion in the study are presented and discussed here. Material and Methods: Between January 2008 and December 2009 a total of 5045 patients in 310 study centers were recruited to the EvaluateTM study. Inclusion criteria were hormone receptor-positive breast cancer and adjuvant treatment or metastasis. 373 patients were excluded from the analysis for various reasons. Results: A total of 4420 patients receiving adjuvant treatment and 252 patients with metastasis receiving palliative treatment were included in the study. For 4181 patients receiving adjuvant treatment, treatment with the aromatase inhibitor letrozole commenced immediately after surgery (upfront). Two hundred patients had initially received tamoxifen and started aromatase inhibitor treatment with letrozole at 1-5 years after diagnosis (switch), und 39 patients only commenced letrozole treatment 5-10 years after diagnosis (extended endocrine therapy). Patient and tumor characteristics were within expected ranges, as were comorbidities and concurrent medication. Conclusion: The data from the EvaluateTM study will offer a good overview of therapy management in the routine care of postmenopausal women with hormone receptor-positive breast cancer. Planned analyses will look at therapy compliance and patient satisfaction with how information is conveyed and the contents of the conveyed information.

引用

页码：1137 / 1143

页数：7

共 50 条

[31] Physical Activity and Survival of Postmenopausal, Hormone Receptor-Positive Breast Cancer Patients Results of the Tamoxifen Exemestane Adjuvant Multicenter Lifestyle Study
de Glas, Nienke A.
Fontein, Duveken B. Y.
Bastiaannet, Esther
Pijpe, Anouk
De Craen, Anton J. M.
Liefers, Gerrit-Jan
Nortier, Hans J. W. R.
de Haes, Hanneke J. C. J. M.
de Velde, Cornelis J. H. van
van Leeuwen, Flora E.
CANCER, 2014, 120 (18) : 2847 - 2854
[32] Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL)
Neugut, Alfred I.
Hillyer, Grace Clarke
Kushi, Lawrence H.
Lamerato, Lois
Leoce, Nicole
Nathanson, S. David
Ambrosone, Christine B.
Bovbjerg, Dana H.
Mandelblatt, Jeanne S.
Magai, Carol
Tsai, Wei-Yann
Jacobson, Judith S.
Hershman, Dawn L.
BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (01) : 419 - 428
[33] Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors
Ballhausen, Alexej
Wheler, Jennifer J.
Karp, Daniel D.
Piha-Paul, Sarina A.
Fu, Siqing
Pant, Shubham
Tsimberidou, Apostolia M.
Hong, David S.
Subbiah, Vivek
Holley, Veronica R.
Huang, Helen J.
Brewster, Abenaa M.
Koenig, Kimberly B.
Ibrahim, Nuhad K.
Meric-Bernstam, Funda
Janku, Filip
CLINICAL CANCER RESEARCH, 2021, 27 (05) : 1247 - 1255
[34] A 2009 Update on the Treatment of Patients with Hormone Receptor-Positive Breast Cancer
Cleator, Susan J.
Ahamed, Eliyaz
Coombes, R. Charles
Palmieri, Carlo
CLINICAL BREAST CANCER, 2009, 9 : S6 - S17
[35] Low p27 Expression Predicts Early Relapse and Death in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients Receiving Adjuvant Tamoxifen Therapy
Filipits, Martin
Rudas, Margaretha
Heinzl, Harald
Jakesz, Raimund
Kubista, Ernst
Lax, Sigurd
Schippinger, Walter
Dietze, Otto
Greil, Richard
Stiglbauer, Wolfgang
Kwasny, Werner
Nader, Alexander
Stierer, Michael
Gnant, Michael F. X.
CLINICAL CANCER RESEARCH, 2009, 15 (18) : 5888 - 5894
[36] A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer
McCaig, Fiona M.
Renshaw, Lorna
Williams, Linda
Young, Oliver
Murray, Juliette
Macaskill, Elizabeth J.
McHugh, Mary
Hannon, Rosemary
Dixon, J. Michael
BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (03) : 643 - 651
[37] Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients
Shimizu, Daisuke
Ishikawa, Takashi
Tanabe, Mikiko
Sasaki, Takeshi
Ichikawa, Yasushi
Chishima, Takashi
Endo, Itaru
BREAST CANCER, 2014, 21 (05) : 557 - 562
[38] Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index
Sendur, M. A. N.
Aksoy, S.
Zengin, N.
Altundag, K.
BRITISH JOURNAL OF CANCER, 2012, 107 (11) : 1815 - 1819
[39] Obesity and Postmenopausal Hormone Receptor-positive Breast Cancer: Epidemiology and Mechanisms
Zuo, Qianying
Band, Shoham
Kesavadas, Mrinali
Madak Erdogan, Zeynep
ENDOCRINOLOGY, 2021, 162 (12)
[40] Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options
Harb, Wael A.
CANCER MANAGEMENT AND RESEARCH, 2015, 7 : 37 - 46

← 1 2 3 4 5 →